Exemplify BioPharma
Private Company
Funding information not available
Overview
Exemplify BioPharma is a specialized CRO offering integrated CMC development and GMP manufacturing services under one roof, primarily from its facility in Cranbury, New Jersey. Its core value proposition is reducing tech-transfer risk and accelerating timelines by providing a single, accountable partner from IND to NDA. As part of the Symeres network since its 2022 acquisition, Exemplify leverages deep scientific expertise in process chemistry, analytical development, and formulation to serve biopharma clients developing both small molecules and biologics. The company operates on a fee-for-service business model, generating revenue by supporting the externalized R&D and manufacturing needs of its clientele.
Technology Platform
Integrated CMC service delivery model with co-located R&D and GMP manufacturing capabilities for drug substance and drug product, focused on reducing tech-transfer risk and accelerating regulatory timelines.
Opportunities
Risk Factors
Competitive Landscape
Exemplify competes in the crowded CMC development and manufacturing services market against large, full-service CDMOs (Catalent, Lonza, Thermo Fisher), other global CROs with CMC arms, and numerous niche specialist firms. Its primary differentiation is the promise of a fully integrated, single-point-of-contact service model designed to eliminate handoff friction, which appeals to clients prioritizing program continuity and risk reduction.